1887

Abstract

Crimean–Congo haemorrhagic fever (CCHF) is a disease with a severe course including acute viral haemorrhagic fever, ecchymosis, thrombocytopenia, hepatic function disorder and high mortality. Myeloperoxidase (MPO) is an enzyme located in neutrophil granulocytes and plays an important role in the destruction of phagocytosed micro-organisms. The aim of this study was to analyse MPO enzyme activity in CCHF cases compared with a control group. A total of 47 randomly selected CCHF patients admitted to the Department of Infectious Diseases of Cumhuriyet University Hospital in Sivas, Turkey, were studied, and as a control group, 41 age- and sex-matched individuals without any systemic disease were included in this study. MPO enzyme activity was measured in plasma and leukocytes for both groups by the ELISA method. MPO plasma and MPO leukocyte values were calculated as 57.62±8.85 and 44.84±9.71 in CCHF patients, and 0.79±0.29 and 0.49±0.11 in the controls, respectively. MPO enzyme activity was statistically significantly higher in patients with CCHF when compared to the control group. In conclusion, MPO enzyme activity is directly related to the activation of phagocytic leukocytes, and increases in both the plasma and leukocytes in CCHF patients. The increase of the MPO enzyme activity in leukocytes due to viral load leads to the destruction of the leukocyte. It is thought that MPO enzyme activity in plasma was higher in CCHF patients due to the destruction of leukocytes. MPO enzyme activity may be important in terms of the prognosis in patients with CCHF; however, more extensive studies are required on this subject.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.047589-0
2013-03-01
2024-12-14
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/3/441.html?itemId=/content/journal/jmm/10.1099/jmm.0.047589-0&mimeType=html&fmt=ahah

References

  1. Acar A. 2006; Crimean-Congo haemorrhagic fever. TAF Prev Med Bull 5:287–295
    [Google Scholar]
  2. Agner K. 1941; Verdoperoxidase: a ferment isolated from leucocytes. Acta Physiol Scand 2:Suppl. 81–62 [CrossRef]
    [Google Scholar]
  3. Altınyazar H. C., Gurel A., Koca R., Armutçu F., Unalacak M. 2006; The status of oxidants and antioxidants in the neutrophils of patients with recurrent aphthous stomatitis. Turk J Med Sci 36:87–91
    [Google Scholar]
  4. Bakir M. 2004; Crimean-Congo hemorrhagic fever. Joint Dis Rel Surg 18:90–93
    [Google Scholar]
  5. Baldus S., Heeschen C., Meinertz T., Zeiher A. M., Eiserich J. P., Münzel T., Simoons M. L., Hamm C. W. on behalf of the CAPTURE Investigators 2003; Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108:1440–1445 [View Article][PubMed]
    [Google Scholar]
  6. Bekheet I. W., Madkour M. E., Abdel Ghaffar N., Nosseir M. M. F., Moussa M. M., Ibraheim R. A., Ateya M. E. 2009; The role of myeloperoxidase in hepatitis C virus infection and associated liver cirrhosis. The Open Tropical Medicine Journal 2:1–7 [View Article]
    [Google Scholar]
  7. Buffon A., Biasucci L. M., Liuzzo G., D’Onofrio G., Crea F., Maseri A. 2002; Widespread coronary inflammation in unstable angina. N Engl J Med 347:5–12 [View Article][PubMed]
    [Google Scholar]
  8. Chochola J., Yamaguchi Y., Moguilevsky N., Bollen A., Strosberg A. D., Stanislawski M. 1994; Virucidal effect of myeloperoxidase on human immunodeficiency virus type 1-infected T cells. Antimicrob Agents Chemother 38:969–972 [View Article][PubMed]
    [Google Scholar]
  9. Deby-Dupont G., Deby C., Lamy M. 1999; Neutrophil myeloperoxidase revisited: its role in health and disease. Intensivmed Notfallmed 36:500–513 [View Article]
    [Google Scholar]
  10. Hampton M. B., Kettle A. J., Winterbourn C. C. 1998; Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92:3007–3017[PubMed]
    [Google Scholar]
  11. Inal M. E. 2007; Fuel oxidation and production of ATP: oxygen toxicity and free radical lesions. In Marks’ Temel Tıbbi Biyokimyası: Klinik yaklaşım pp. 439–458 Edited by Smith C., Marks A. D., Lieberman M. Translation editors Inal M. E., Atik U., Aksoy N., Haşimi A. Ankara:
    [Google Scholar]
  12. Işeri S. O., Sener G., Saglam B., Gedik N., Ercan F., Yegen B. C. 2005; Oxytocin protects against sepsis-induced multiple organ damage: role of neutrophils. J Surg Res 126:73–81 [View Article][PubMed]
    [Google Scholar]
  13. Kara A. 2006; Crimean-Congo haemorrhagic fever. Çocuk Saǧliǧi ve Hastaliklari Dergisi 49:175–184 (in Turkish)
    [Google Scholar]
  14. Karti S. S., Odabasi Z., Korten V., Yilmaz M., Sonmez M., Caylan R., Akdogan E., Eren N., Koksal I. other authors 2004; Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis 10:1379–1384 [View Article][PubMed]
    [Google Scholar]
  15. Kaya M. G., Yalçın R., Okyay K., Poyraz F., Bayraktar N., Timurkaynak T., Ozdemir M., Cemri M., Abacı A. other authors 2005; Relationship between plasma myeloperoxidase level and extent coronary artery involvement and early prognosis in acute ST elevation myocardial infarction. Tıp Araştırmaları Dergisi 3:27–31 (in Turkish)
    [Google Scholar]
  16. Kothari N., Keshari R. S., Bogra J., Kohli M., Abbas H., Malik A., Dikshit M., Barthwal M. K. 2011; Increased myeloperoxidase enzyme activity in plasma is an indicator of inflammation and onset of sepsis. J Crit Care 26:435.e1–e7 [View Article][PubMed]
    [Google Scholar]
  17. Kulander L., Pauksens K., Venge P. 2001; Soluble adhesion molecules, cytokines and cellular markers in serum in patients with acute infections. Scand J Infect Dis 33:290–300 [View Article][PubMed]
    [Google Scholar]
  18. Lupi O., Tyring S. K. 2003; Tropical dermatology: viral tropical diseases. J Am Acad Dermatol 49:979–1000 [View Article][PubMed]
    [Google Scholar]
  19. Mardani M., Keshtkar-Jahromi M. 2007; Crimean-Congo hemorrhagic fever. Arch Iran Med 10:204–214[PubMed]
    [Google Scholar]
  20. Mehrabi-Tavana A., Chinikar S., Mazaheri V. 2002; The seroepidemiological aspects of Crimean-Congo hemorrhagic fever in three health workers: a report from Iran. Arch Iran Med 5:255–258
    [Google Scholar]
  21. Michowitz Y., Kisil S., Guzner-Gur H., Rubinstein A., Wexler D., Sheps D., Keren G., George J. 2008; Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart failure. Isr Med Assoc J 10:884–888[PubMed]
    [Google Scholar]
  22. Miyasaki K. T., Zambon J. J., Jones C. A., Wilson M. E. 1987; Role of high-avidity binding of human neutrophil myeloperoxidase in the killing of Actinobacillus actinomycetemcomitans . Infect Immun 55:1029–1036[PubMed]
    [Google Scholar]
  23. Morrow D. A., Sabatine M. S., Brennan M. L., De Lemos J. A., Murphy S. A., Ruff C. T., Rifai N., Cannon C. P., Hazen S. L. 2008; Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 29:1096–1102 [View Article][PubMed]
    [Google Scholar]
  24. Olsson I., Bulow E., Hansson M. 2004; Biosynthesis and sorting of myeloperoxidase in hematopoietic cells. Jpn J Infect Dis 57:13–14
    [Google Scholar]
  25. Re G., Azzimondi G., Lanzarini C., Bassein L., Vaona I., Guarnieri C. 1997; Plasma lipoperoxidative markers in ischaemic stroke suggest brain embolism. Eur J Emerg Med 4:5–9[PubMed]
    [Google Scholar]
  26. Rocha V., Franco R. F., Porcher R., Bittencourt H., Silva W. A. Jr, Latouche A., Devergie A., Esperou H., Ribaud P. other authors 2002; Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 100:3908–3918 [View Article][PubMed]
    [Google Scholar]
  27. Ronald J. A., Chen J. W., Chen Y., Hamilton A. M., Rodriguez E., Reynolds F., Hegele R. A., Rogers K. A., Querol M. other authors 2009; Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation 120:592–599 [View Article][PubMed]
    [Google Scholar]
  28. Schnittler H. J., Feldmann H. 2003; Viral hemorrhagic fever–a vascular disease?. Thromb Haemost 89:967–972[PubMed]
    [Google Scholar]
  29. Swanepoel R., Shepherd A. J., Leman P. A., Shepherd S. P., McGillivray G. M., Erasmus M. J., Searle L. A., Gill D. E. 1987; Epidemiologic and clinical features of Crimean-Congo hemorrhagic fever in southern Africa. Am J Trop Med Hyg 36:120–132[PubMed]
    [Google Scholar]
  30. Tang W. H., Tong W., Troughton R. W., Martin M. G., Shrestha K., Borowski A., Jasper S., Hazen S. L., Klein A. L. 2007; Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 49:2364–2370 [View Article][PubMed]
    [Google Scholar]
  31. Valenzuela A. 1991; The biological significance of malondialdehyde determination in the assessment of tissue oxidative stress. Life Sci 48:301–309 [View Article][PubMed]
    [Google Scholar]
  32. Vestweber D. 2007; Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium. Immunol Rev 218:178–196 [View Article][PubMed]
    [Google Scholar]
  33. Winterbourn C. C., Vissers M. C., Kettle A. J. 2000; Myeloperoxidase. Curr Opin Hematol 7:53–58 [View Article][PubMed]
    [Google Scholar]
  34. Wright J., Bastian N., Davis T. A., Zuo C., Yoshimoto S., Orme-Johnson W. H., Tauber A. I. 1990; Structural characterization of the isoenzymatic forms of human myeloperoxidase: evaluation of the iron-containing prosthetic group. Blood 75:238–241[PubMed]
    [Google Scholar]
  35. Zelzer S., Stiegler P., Kapitan M., Schaffellner S., Schweiger M., Stettin M., Stojakovic T., Truschnig-Wilders M., Tscheliessnigg K. H., Khoschsorur G. 2009; Myeloperoxidase as serum marker for detection of CMV infections and rejections in patients after liver or heart transplantation. Transpl Immunol 20:121–126 [View Article][PubMed]
    [Google Scholar]
  36. Zhang R., Brennan M. L., Fu X., Aviles R. J., Pearce G. L., Penn M. S., Topol E. J., Sprecher D. L., Hazen S. L. 2001; Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286:2136–2142 [View Article][PubMed]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.047589-0
Loading
/content/journal/jmm/10.1099/jmm.0.047589-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error